Skip to main content

Page last checked

Research compound · not FDA-approved

Enicepatide

Also called CT-388, RO7795068 or RG6640.

Enicepatide is an experimental weekly shot being studied for weight loss. It turns on both GLP-1 and GIP receptors.

What matters first

Why people look it up
Researchers are studying Enicepatide for weight loss.
What the evidence shows
A peer-reviewed Phase 1 study reported weight loss. Roche later reported a Phase 2 result. Enicepatide is not FDA-approved.
Dose status
Enicepatide is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study3 reported dose rows
Safety evidence
No listed safety findingsNo reactions reported here
Sources
10 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
Enicepatide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how it works · how good the evidence is · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Enicepatide

Enicepatide is an experimental weekly shot being studied for weight loss. It turns on both GLP-1 and GIP receptors. Its previous name was CT-388.

A peer-reviewed Phase 1 study measured body weight after 4 weeks. Average weight was 4.7% to 8.0% lower across study groups. It was 0.5% lower with placebo.

Roche later reported a 48-week Phase 2 result. At the highest dose, placebo-adjusted weight loss was 22.5% under one analysis. It was 18.3% under another. Enicepatide is not FDA-approved.

Enicepatide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourceHuman trial
FDA approvalNot FDA-approved
Studied dosing0.5–7.5 mg one subcutaneous dose in the Phase 1 single-dose study — from clinical trials
Studied dosing5–12 mg once weekly for four doses in Phase 1, with study-set increases that differed by group — from clinical trials
Studied dosing24 mg once weekly after study-set increases in the 48-week Phase 2 trial; 24 mg was the highest target tested — from clinical trials
PresentationEnicepatide has no approved vial or mixing instructions; its studies use prepared research injections.

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

How Enicepatide works

Enicepatide acts at GIP + GLP-1. Here is what that means.

A dual agonist switches on the receptors for both hormones your gut releases after eating: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both were first understood as insulin boosters, and combining them started out as a diabetes idea. The weight loss that followed was bigger than the GLP-1 half alone would explain, and researchers still do not agree on why.

◆ Receptor targets2 of 4 · GIP + GLP-1
4What each receptor does — 4 rows in the data table
Receptors targeted by Enicepatide, and what each receptor does
ReceptorEnicepatideWhat it does
GLP-1targetedInsulin release while blood sugar is rising, less glucagon, slower stomach emptying, and less appetite — the same physiology a single-target drug produces, carried here by the same molecule.
GIPtargetedpancreatic isletGIP is the other gut hormone, released higher up the small intestine. It boosts insulin alongside GLP-1, which is why the two together move blood sugar more than either does alone.adipose tissue and brainGIP receptors also sit on fat cells. There, the hormone has a hand in how nutrients get stored and how blood moves through fat tissue. These receptors also sit in the brain regions handling appetite and nausea. What GIP actually contributes to weight loss is disputed — blocking the same receptor has also produced benefit in experiments.
Glucagonnot targeted—
Amylinnot targeted—

The same four receptor groups are shown for every drug, so the differences are easy to compare. Targets come from the drug class. Any result specific to Enicepatide comes from the cited sources.

The honest summary: the two-receptor design has beaten single-target GLP-1 in trials, and the explanation is unfinished. One leading idea is that GIP signaling in the brain dampens the nausea that limits GLP-1 dosing. In that hypothesis, a dual agonist can be pushed further before side effects stop it. That is a hypothesis, not a finding — any confident story about what GIP does is running ahead of the evidence.

What the evidence for Enicepatide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial
What it establishes
The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

Where Enicepatide is in clinical trials

8 registered studies; the program has reached phase 3, and 4 are still enrolling.

The soonest a running study expects to finish measuring people is May 2027. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

  • Phase 3Recruiting

    A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

    Hoffmann-La Roche · Obesity, Overweight · 300 participants planned · started July 2026

    Main measurement due February 2028 (sponsor estimate)

    NCT07670416 on ClinicalTrials.gov

  • Phase 3Recruiting

    A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

    Hoffmann-La Roche · Obesity or Overweight, Type 2 Diabetes Mellitus · 1,600 participants planned · started March 2026

    Main measurement due August 2028 (sponsor estimate)

    NCT07351058 on ClinicalTrials.gov

  • Phase 3Recruiting

    A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

    Hoffmann-La Roche · Obesity or Overweight · 2,000 participants planned · started March 2026

    Main measurement due July 2028 (sponsor estimate)

    NCT07351045 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-07

Every compound we track, and what stage each one has reached →

Regulatory status

Enicepatide is investigational.

It has no approved product, prescribing schedule, retail price or availability date. The Phase 1 findings come from small groups followed for four weeks. The Phase 2 figures come from a sponsor release, while ClinicalTrials.gov posts no results for that study.

Full regulatory tracker →

Where to go next on Enicepatide

Every dosing schedule, including enicepatide

7 pages carry trial arms — which is a different object from a chart, with enicepatide as context

Vial, water and dose for any peptide, with enicepatide as one example

U-100, U-50 and U-40 barrels each read differently, including enicepatide

Petrelintide on its own page, separate from enicepatide

Petrelintide has published human trial data, separate from enicepatide.

Survodutide in the full list, alongside enicepatide

No published half-life for survodutide, cited apart from enicepatide.

Pemvidutide in the full list, alongside enicepatide

No published half-life for pemvidutide, cited apart from enicepatide.

What the mazdutide page carries, separate from enicepatide

6 sourced mazdutide reactions, on its own page, separate from enicepatide.

What the zenagamtide page carries, separate from enicepatide

2 sourced zenagamtide reactions, on its own page, separate from enicepatide.

Eloralintide in the full list, alongside enicepatide

No published half-life for eloralintide, cited apart from enicepatide.

Cagrilintide on its own page, separate from enicepatide

Cagrilintide has published human trial data, separate from enicepatide.

The source-checked liraglutide entry, beyond the enicepatide one

An approved liraglutide label exists — beyond enicepatide.

Safety notes

  • In the four-dose Phase 1 groups, the most common reported events included reduced appetite, nausea, vomiting and diarrhea
  • The Phase 1 paper says most treatment-emergent events were mild or moderate; its small groups do not establish long-term safety
  • Roche reported Phase 2 discontinuation because of adverse events in 5.9% of Enicepatide groups versus 1.3% with placebo
  • The Phase 2 result and safety summary were reported by the company. ClinicalTrials.gov does not post results for that study
  • No FDA-approved product, prescribing schedule, price or availability date exists

Questions about Enicepatide

Is Enicepatide FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Enicepatide taken?

By injection under the skin, one subcutaneous dose in the Phase 1 single-dose study.

How does Enicepatide differ from the other compounds in this class?

It acts at GIP + GLP-1. Adding or removing a receptor changes the effect. It also changes how much people can tolerate. These molecules are not swappable at the same number of milligrams. Comparing them milligram for milligram is the most common mistake in this category.

The nearest alternatives act elsewhere:

  • Semaglutide (GLP-1 alone)
  • Liraglutide (GLP-1 alone)
  • Retatrutide (GIP + GLP-1 + glucagon)
  • Cagrilintide (amylin)
  • Survodutide (glucagon + GLP-1)
  • Mazdutide (glucagon + GLP-1)
  • Zenagamtide (GLP-1 + amylin)
  • Pemvidutide (glucagon + GLP-1)
  • Eloralintide (amylin)
  • Petrelintide (amylin)

What is not known about Enicepatide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

10primary sources, each with the day we read it — open the documents used on this page